Authors: Mistry, P Stewart, AJ Dangerfield, W Okiji, S Liddle, C Bootle, D Plumb, JA Templeton, D Charlton, P

Citation: P. Mistry et al., In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576, CANCER RES, 61(2), 2001, pp. 749-758

Authors: Mirochnik, O Halim-Kertanegara, N Hertzberg, M McDonald, D Liddle, C

Citation: O. Mirochnik et al., Incorrect diagnosis of hereditary hemochromatosis, AM J HEMAT, 63(2), 2000, pp. 104-105

Authors: Khan, MH Farrell, GC Byth, K Lin, R Weltman, M George, J Samarasinghe, D Kench, J Kaba, S Crewe, E Liddle, C

Citation: Mh. Khan et al., Which patients with hepatitis C develop liver complications?, HEPATOLOGY, 31(2), 2000, pp. 513-520

Authors: Moore, LB Parks, DJ Jones, SA Bledsoe, RK Consler, TG Stimmel, JB Goodwin, B Liddle, C Blanchard, SG Willson, TM Collins, JL Kliewer, SA

Citation: Lb. Moore et al., Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands, J BIOL CHEM, 275(20), 2000, pp. 15122-15127

Authors: Goodwin, B Hodgson, E Liddle, C

Citation: B. Goodwin et al., The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module, MOLEC PHARM, 56(6), 1999, pp. 1329-1339

Authors: Dutta, U Byth, K Kench, J Khan, MH Coverdale, SA Weltman, M Lin, R Liddle, C Farrell, GC

Citation: U. Dutta et al., Risk factors for development of hepatocellular carcinoma among Australianswith hepatitis C: a case-control study, AUST NZ J M, 29(3), 1999, pp. 300-307